(15088446), S. Y., (15352614), S. S., (15352611), D. S., (15033960), T. N., (22547757), A. O., (15352623), M. Y., . . . (15352635), A. H. (2025). Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models.
Chicago-referens (17:e uppl.)(15088446), Shigehiro Yagishita, et al. Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models. 2025.
MLA-referens (9:e uppl.)(15088446), Shigehiro Yagishita, et al. Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models. 2025.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.